Extended Data Table 5 Adverse events with a possible immune-mediated cause and infusion reactions in the as-treated population

From: The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

  1. Adverse events with a possible immune-mediated cause and infusion reactions were considered regardless of attribution to study treatment by the investigator. The specific events are based on a list of terms provided by the sponsor. In addition to the specific terms listed, related terms were also included.
Back to article page